Renate Udo1,2, Anke H Maitland-van der Zee1, Toine C G Egberts1,3, Johanna H den Breeijen1,3, Hubert G M Leufkens1,2, Wouter W van Solinge1,4, Marie L De Bruin1,2. 1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands. 2. Medicines Evaluation Board, Utrecht, The Netherlands. 3. Department of Clinical Pharmacy, University Medical Center Utrecht, The Netherlands. 4. Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
PURPOSE: The development and validation of algorithms to identify cases of idiopathic acute liver injury (ALI) are essential to facilitate epidemiologic studies on drug-induced liver injury. The aim of this study is to determine the ability of diagnostic codes and laboratory measurements to identify idiopathic ALI cases. METHODS: In this cross-sectional validation study, patients were selected from the hospital-based Utrecht Patient Oriented Database between 2008 and 2010. Patients were identified using (I) algorithms based on ICD-9-CM codes indicative of idiopathic ALI combined with sets of liver enzyme values (ALT > 2× upper limit of normal (ULN); AST > 1ULN + AP > 1ULN + bilirubin > 1ULN; ALT > 3ULN; ALT > 3ULN + bilirubin > 2ULN; ALT > 10ULN) and (II) algorithms based on solely liver enzyme values (ALT > 3ULN + bilirubin > 2ULN; ALT > 10ULN). Hospital medical records were reviewed to confirm final diagnosis. The positive predictive value (PPV) of each algorithm was calculated. RESULTS: A total of 707 cases of ALI were identified. After medical review 194 (27%) patients had confirmed idiopathic ALI. The PPV for (I) algorithms with an ICD-9-CM code as well as abnormal tests ranged from 32% (13/41) to 48% (43/90) with the highest PPV found with ALT > 2ULN. The PPV for (II) algorithms with liver test abnormalities was maximally 26% (150/571). CONCLUSIONS: The algorithm based on ICD-9-CM codes indicative of ALI combined with abnormal liver-related laboratory tests is the most efficient algorithm for identifying idiopathic ALI cases. However, cases were missed using this algorithm, because not all ALI cases had been assigned the relevant diagnostic codes in daily practice.
PURPOSE: The development and validation of algorithms to identify cases of idiopathic acute liver injury (ALI) are essential to facilitate epidemiologic studies on drug-induced liver injury. The aim of this study is to determine the ability of diagnostic codes and laboratory measurements to identify idiopathic ALI cases. METHODS: In this cross-sectional validation study, patients were selected from the hospital-based Utrecht Patient Oriented Database between 2008 and 2010. Patients were identified using (I) algorithms based on ICD-9-CM codes indicative of idiopathic ALI combined with sets of liver enzyme values (ALT > 2× upper limit of normal (ULN); AST > 1ULN + AP > 1ULN + bilirubin > 1ULN; ALT > 3ULN; ALT > 3ULN + bilirubin > 2ULN; ALT > 10ULN) and (II) algorithms based on solely liver enzyme values (ALT > 3ULN + bilirubin > 2ULN; ALT > 10ULN). Hospital medical records were reviewed to confirm final diagnosis. The positive predictive value (PPV) of each algorithm was calculated. RESULTS: A total of 707 cases of ALI were identified. After medical review 194 (27%) patients had confirmed idiopathic ALI. The PPV for (I) algorithms with an ICD-9-CM code as well as abnormal tests ranged from 32% (13/41) to 48% (43/90) with the highest PPV found with ALT > 2ULN. The PPV for (II) algorithms with liver test abnormalities was maximally 26% (150/571). CONCLUSIONS: The algorithm based on ICD-9-CM codes indicative of ALI combined with abnormal liver-related laboratory tests is the most efficient algorithm for identifying idiopathic ALI cases. However, cases were missed using this algorithm, because not all ALI cases had been assigned the relevant diagnostic codes in daily practice.
Authors: Nancy D Lin; Heather Norman; Arie Regev; David G Perahia; Hu Li; Curtis Liming Chang; David D Dore Journal: BMC Gastroenterol Date: 2015-10-14 Impact factor: 3.067
Authors: Manel Pladevall-Vila; Anton Pottegård; Tania Schink; Johan Reutfors; Rosa Morros; Beatriz Poblador-Plou; Antje Timmer; Joan Forns; Maja Hellfritzsch; Tammo Reinders; David Hägg; Maria Giner-Soriano; Alexandra Prados-Torres; Miguel Cainzos-Achirica; Jesper Hallas; Lena Brandt; Jordi Cortés; Jaume Aguado; Gabriel Perlemuter; Bruno Falissard; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann Journal: CNS Drugs Date: 2019-04 Impact factor: 5.749
Authors: Joan Forns; Miguel Cainzos-Achirica; Maja Hellfritzsch; Rosa Morros; Beatriz Poblador-Plou; Jesper Hallas; Maria Giner-Soriano; Alexandra Prados-Torres; Anton Pottegård; Jordi Cortés; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann; Manel Pladevall Journal: Pharmacoepidemiol Drug Saf Date: 2019-06-06 Impact factor: 2.890
Authors: Stefanie Amelung; David Czock; Markus Thalheimer; Torsten Hoppe-Tichy; Walter E Haefeli; Hanna M Seidling Journal: J Clin Med Date: 2022-07-23 Impact factor: 4.964